Document is current
Any future updates will be listed below
-
Authors
Abplanalp, Samuel J. https://orcid.org/0000-0003-2894-5607
Green, Michael F.
Wynn, Jonathan K. https://orcid.org/0000-0002-1763-8540
Eisenberger, Naomi I.
Horan, William P.
Lee, Junghee https://orcid.org/0000-0001-9567-8700
McCleery, Amanda
Miklowitz, David J.
Reddy, L. Felice
Reavis, Eric A. https://orcid.org/0000-0002-9843-9139
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH110470)
- License Information
-
More Information
Article History
Received: 19 July 2024
Accepted: 13 September 2024
First Online: 5 October 2024
Competing interests
: M.F.G. has been a speaker for Boehringer Ingelheim and Sumitomo Dainippon Pharma. W.P.H. is an employee of and holds equity in Karuna Therapeutics. A.Mc. has received research funding from Alkermes PLC, and payment for assessment services from MedAvante-Prophase. D.J.M. has received research funding from the Danny Alberts Foundation, the Attias Family Foundation, the Carl and Roberta Deutsch Foundation, the Kayne Family Foundation, and AIM for Mental Health; and book royalties from Guilford Press and John Wiley and Sons. The other authors do not have any conflict of interest.
